Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund

Kyle Blankenship

Nearly a year into the Covid-19 pandemic, a wave of investment in novel therapies and vaccines to fight the virus has continued to flow—and investors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund

Kyle Blankenship

Sign up to read this article for free.

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Bristol Myers sues the federal government over 340B, following other drugmakers

Dri­ven by Covid-19 fever, For­bion notes in­vestor in­ter­est in vac­cines and new ther­a­pies as part of $557M fund

Kyle Blankenship

Sign up to read this article for free.

more like this

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Bristol Myers sues the federal government over 340B, following other drugmakers